The Project Santa Fe Foundation and Virchow Medical have announced a strategic partnership aimed at transforming laboratory data into actionable clinical insights for oncology patients. This collaboration leverages Virchow Medical’s Crow’s Nest Biopsy Catchment System and Virchow Vault Liquid Specimen Biorepository to maximize the collection of high-quality biospecimens, enabling more predictive and proactive analytics in clinical laboratory medicine. The initiative aligns with the Clinical Lab 2.0 movement, which seeks to shift healthcare from a reactive model of treating illness to a predictive framework that emphasizes early intervention and improved patient outcomes.
Health Technology Insights: Corus Orthodontists Secures C$20 Million Equity Investment
Khosrow Shotorbani, CEO of Clinical Lab 2.0 and the Diagnostic Medicine Consortium, explained that the partnership harnesses the power of longitudinal patient data. He stated that by integrating Virchow Medical’s unique technologies with PSFF’s Clinical Lab 2.0 infrastructure, both organizations are positioned to enhance healthcare integration, improve clinical decision-making, and ultimately support better patient outcomes. The collaboration builds on the Diagnostic Medicine Consortium, co-founded by PSFF and the Association of Pathology Informatics, which provides the governance and ethical framework needed to operationalize these strategies in real-world clinical environments.
The partnership includes several key initiatives. First, de-identified data augmentation will enable researchers to build consent-driven data resources that expand the predictive value of laboratory diagnostics, including cancer biomarkers and digital pathology. Second, Virchow Medical’s biospecimen infrastructure repurposes cells from used biopsy needles, which would otherwise be medical waste, to create a high-quality repository for oncology research. Third, advanced algorithm development will utilize these combined data sources to train artificial intelligence tools capable of early detection, cost avoidance, causal analysis, and targeted therapy recommendations. Fourth, regulatory collaboration will ensure the ethical and compliant use of the Virchow Vault for novel AI-driven diagnostic applications. Finally, educational programs will teach laboratory and pathology professionals how to fully leverage these cellular resources and predictive analytics to improve clinical practice.
James M. Crawford, MD, PhD, Chair of the Boards of PSFF and the Diagnostic Medicine Consortium, emphasized that the Crow’s Nest Biopsy Catchment System provides a practical method to routinely capture and preserve tumor cells from core needle biopsies, reducing the risk of sample insufficiency and supporting more reliable diagnostic outcomes. Alexander Arrow, MD, CEO of Virchow Medical, highlighted that the partnership strengthens the company’s commitment to proactive analytics, regulatory compliance, and improved cancer care through reduced false negatives and enhanced laboratory services.
The Project Santa Fe Foundation is a nonprofit organization dedicated to advancing Clinical Lab 2.0 by bringing together laboratory leaders to develop standards, evidence, and informatics solutions that expand the role of diagnostics in the future healthcare ecosystem. Through this collaboration with Virchow Medical, PSFF continues to drive innovation in laboratory medicine, demonstrating the potential of integrated data and biospecimen resources to transform patient care in oncology.
Health Technology Insights: SEQSTER Expands Partnership with Praxis Precision Medicines
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
